I was diagnosed in 2012 with stage IV acinar cell carcinoma. This type by itself does not show elevation in CA19-9 by itself as acinar cells do not secrete this biomarker. A rise in CA19-9 may have been the result of an inflammatory process secondary to your PACC tumor.

I also have a germline BRCA2 mutation and after 24 months of more aggressive treatment with Folfirinox beyond what is done for standard of care for which I had to advocate for, I was the first pancreatic cancer patient in the US to enroll in the RucaPANC clinical trial testing a PARPi inhibitor called Rucaparib (Rubraca) which is a biosimilar to Lynparza. By the conclusion of the trial, I had a complete response to the PARPi and was allowed by the FDA to continue on it as it as an application for FDA approval has not yet been made.

I am the longest former pancreatic cancer patient in the world on this PARPi for maintenance monotherapy at 9.5 years and have been declared not just N.E.D., but cured of metastatic PACC and thriving 11 3/4 years after my diagnosis.